Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. - Test2 - elhamkhani - TriplyDB

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q52887503

about

Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study Effect of Radial Shock Wave Therapy on Spasticity of the Upper Limb in Patients With Chronic Stroke: A Prospective, Randomized, Single Blind, Controlled Trial.Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis.A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity.Cyclic functional electrical stimulation does not enhance gains in hand grasp function when used as an adjunct to onabotulinumtoxinA and task practice therapy: a single-blind, randomized controlled pilot study.Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin.Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence?OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review.Quality of the stroke rehabilitation research.An evidence-based review of stroke rehabilitation.Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom.Botulinum toxin a does not decrease calf pain or improve ROM during limb lengthening: a randomized trial.Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial.Evaluating the role of botulinum toxin in the management of focal hypertonia in adults.The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.Rehabilitation medicine: 3. Management of adult spasticity.Neuronox versus BOTOX in the Treatment of Post-Stroke Upper Limb Spasticity: A Multicenter Randomized Controlled Trial Physiological effects of botulinum toxin in spasticity.Botulinum toxins in neurological disease.Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.Changes in Cerebellar Activation After Onabotulinumtoxin A Injections for Spasticity After Chronic Stroke: A Pilot Functional Magnetic Resonance Imaging Study.Consequences of neurologic lesions assessed by Barthel Index after Botox(®) injection may be underestimated.Management of spasticity in adults: practical application of botulinum toxin.Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia.Botulinum toxin type A combined with neurodynamic mobilization for lower limb spasticity: a case report Botulinum toxin in poststroke spasticity Shock wave over hand muscles: a neurophysiological study on peripheral conduction nerves in normal subjects Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity.Spasticity treatment with botulinum toxins.Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review.Ambulatory rehabilitation in multiple sclerosis.Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections.Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis.

P2860

Q26750450-CE273D87-A3D1-4F3D-B655-DCFBBD8438EA Q26766544-E51EEB41-763C-478F-9524-C115FF28A98E Q28257329-8B347C22-3A49-4A07-AF7B-26C8DE71BCDD Q30382491-2F8572FF-B832-4F01-B7D7-ED2BD31CC5F0 Q30538210-4100FC06-015A-4F5E-BBE7-D98B692BCE83 Q33723150-7E5ADD2C-3B43-4547-8562-8373958A90AA Q33739127-2392C4EE-2C36-49A5-AE61-E176171AC918 Q33894347-AF7986E9-9E25-4D55-B5E3-8F43B4824392 Q34041378-4909B507-F076-4EBA-AB1D-364AB8B380C3 Q34579725-4292080C-CD23-47E0-98F7-7E384FBD6489 Q34980467-0121D916-E2CE-4BBF-B4DA-B7751D4718D7 Q35217428-948E522C-1D01-4465-80DC-98D9B22AAE9E Q35217431-9567227B-55F5-4E18-836F-9287B899B4F3 Q35284574-DDD3BCC4-1BC9-4E16-AE1A-6D47BCA14DFC Q35425673-74BE686B-4792-4E1E-ABB3-0703339FC692 Q35458739-1943ECAF-BCCD-4C47-ACE7-D30D38615D55 Q35459787-CB5BD221-9BE9-47B1-973E-20F257FD5DBA Q35477882-1499C0EC-50E5-4C36-914D-4E6A835FBFE1 Q35478000-B3373F01-6352-4148-8700-BB8D33F73986 Q35593147-79165A07-12A2-4E30-AA83-08CACB92A437 Q35647787-C62D9273-8A94-4507-AED4-41AFB0681BA7 Q35693999-9E71211D-BCE7-4E04-A39D-776C4E5C8DF4 Q35759634-17EE1404-D80F-4CA1-8813-942F740612FF Q36227094-D5556ECD-7888-4F40-86BC-E41C76268A0C Q36235985-2020DF65-5F4A-4F32-BA53-F86A0380DFB8 Q36344663-EA08FBCE-05F7-484B-9F0C-C7AB1567A548 Q36370640-BBE50D20-87B6-462C-B942-E55E6AACE032 Q36384711-7E1C6857-826C-4C2B-8E79-0BA6F392F7CA Q36643323-A22BE023-1652-4C60-B86E-4011CF19328F Q36724869-686B9ABE-EDB4-45F3-8DE7-7F18DC6AA29E Q36868342-8B281759-9B95-4168-AB1D-DC9474398F3D Q36883503-2E50AE0E-347F-4E12-A12B-3C58188CB75A Q37032412-3998A724-128C-46B3-9150-3FA6C05476CD Q37103149-9341AE89-AEEC-463B-A04C-4B32A5C26438 Q37128763-64079890-986B-4F52-B95A-A00A812A6D9E Q37340491-A62C938E-4A45-452A-AAA4-EF67F7DF21F8 Q37395495-B0D3C2B8-CD25-4502-9C34-E267DD009D7F Q37500121-989D9921-2D40-4017-AFED-7C84A5103A8E Q37596170-7A520A9B-2DFC-4340-A3B3-FF7C02189FFB Q37759065-CC12ACD0-9EE6-47AD-804B-C3314B95AB48

P2860

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q52887503

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh-hant

name

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@en

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@nl

type

label

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@en

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@nl

prefLabel

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@en

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@nl

P1433

Q52887503-36B4697A-22FC-4574-BA15-9A0DCF2057B4

P1476

Q52887503-67269F56-6991-4D27-BA55-35F7EC3BB39D

P2093

Q52887503-15F4008E-1C95-4185-856F-1E5029E36F7C

Q52887503-4D21DD7A-ECAB-4530-A145-8E1594495204

Q52887503-6D66C883-4669-4EEE-A9A9-60AA3A7E2A02

Q52887503-7251E272-CD2C-4E22-84AA-F383DBB04895

Q52887503-7761B949-ECE0-48A7-B509-E5DE1B055EB6

Q52887503-80BAC32B-598E-4110-A9CC-B3B1D36079C3

Q52887503-897EA793-FB00-424A-B8AE-C6FC8EEDC0A4

Q52887503-C17D6FBF-F345-4328-967C-A2D57CE706F5

Q52887503-EE240AD6-ED25-440E-A5B2-232619A947C8

P304

Q52887503-4789557E-355C-4DF1-8F9F-8609A68330C9

P31

Q52887503-814B5331-2DCF-494D-A364-547A150ED653

P356

Q52887503-4B4F0488-019F-4AA4-8C61-9801DEDE41A4

P407

Q52887503-04BBC8C3-D02C-4E33-B730-75411B55D9A7

P433

Q52887503-9516F7B9-1501-4D37-9D80-00D0A90EDABA

P478

Q52887503-6165B99D-1C46-4E0F-8E69-8C9A9D94241F

P577

Q52887503-7E6C59C9-0448-43CA-AC40-2014CF5FD1EC

P5875

Q52887503-8E4D89CE-7ED3-4E09-9C4E-1FD64508563F

P698

Q52887503-86B1DD64-EED9-4480-80E7-A3F87D8D4C0B

P921

Q52887503-A89742B0-A68D-48BD-969B-AFD7795F02EC

P356

P1433

P1476

Botulinum toxin type A in the ...... ind, placebo-controlled trial.

@en

P2093

Alexander DN

http://www.w3.org/2001/XMLSchema#string

Aswad AS

http://www.w3.org/2001/XMLSchema#string

Gibson J

http://www.w3.org/2001/XMLSchema#string

Leon JM

http://www.w3.org/2001/XMLSchema#string

Monaghan EP

http://www.w3.org/2001/XMLSchema#string

Mordaunt JM

http://www.w3.org/2001/XMLSchema#string

O'Brien CF

http://www.w3.org/2001/XMLSchema#string

Simpson DM

http://www.w3.org/2001/XMLSchema#string

Tagliati M

http://www.w3.org/2001/XMLSchema#string

P304

1306-1310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.46.5.1306

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

1996-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14571033

http://www.w3.org/2001/XMLSchema#string

P698

8628472

http://www.w3.org/2001/XMLSchema#string

P921